108736-35-2

108736-35-2 structure

Name: Lanreotide acetate salt
Chemical Name: Lanreotide
CAS Number: 108736-35-2
Molecular Formula: C₅₄H₆₉N₁₁O₁₀S₂
Molecular Weight: 1096.323
Catalog: Research Areas Cancer
Create Date: 2018-08-22 10:15:18
Modify Date: 2024-01-04 14:03:43
Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome[1][2].

Name	Lanreotide
Synonyms	B-naphthyl-D-ala-cys-tyr-D-trp*lys-val-cys-thr am 1,2-Dithia-5,8,11,14,17-pentaazacycloeicosane-4-carboxamide, 10-(4-aminobutyl)-N-[1-(aminocarbonyl)-2-hydroxypropyl]-19-[[2-amino-3-(2-naphthalenyl)-1-oxopropyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-6,9,12,15,18-pentaoxo- 10-(4-Aminobutyl)-N-(1-amino-3-hydroxy-1-oxo-2-butanyl)-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-isopropyl-19-{[3-(2-naphthyl)alanyl]amino}-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide Somatuline AUTOGEL ANGIOPEPTIN IPSTYL DC-13-116 10-(4-Aminobutyl)-N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-isopropyl-19-{[3-(2-naphthyl)alanyl]amino}-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2

Description	Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome[1][2].
Related Catalog	Research Areas >> Cancer Research Areas >> Endocrinology Signaling Pathways >> Others >> Others
In Vitro	Lanreotide (BIM 23014) (100 nM; 24-48 h) combines with radiation increasing in apoptotic sub-G1 proportion[1]. Lanreotide results in a dose-dependent decrease in GH3 cell colony forming units. Lanreotide at concentrations of 1, 10, 100, and 1000 nM results in cell survival rates of 75, 56, 39 and 27% respectively. The IC50 is 57 nM[1]. Lanreotide inhibits GH-secreting pituitary adenoma cell proliferation and hormone release in vitro[2].
In Vivo	Lanreotide (2.5-10mg/kg; s.c.; daily for 5 days) results in tumor growth inhibition[1]. Animal Model: Male nude mice, 8 weeks old and 20–25 g in body weight (GH3 tumor-bearing nude mice)[1] Dosage: 2.5, 5, 10 mg/kg Administration: Subcutaneous; daily for 5 days Result: Produced tumor growth inhibition.
References	[1]. Ning S, et al. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.Endocr Relat Cancer. 2009 Sep;16(3):1045-55. [2]. Florio T, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.Clin Endocrinol (Oxf). 2003 Jul;59(1):115-28.